Merrimack Pharmaceuticals Inc (MACK)

15.21
0.44 3.00
NASDAQ : Health Care
Prev Close 14.77
Open 14.74
Day Low/High 14.65 / 15.16
52 Wk Low/High 5.02 / 11.18
Volume 27.87K
Avg Volume 164.50K
Exchange NASDAQ
Shares Outstanding 13.28M
Market Cap 192.83M
EPS -12.10
Div & Yield N.A. (N.A)

Latest News

Merrimack Announces Date Of One-for-Ten Reverse Stock Split

Merrimack Announces Date Of One-for-Ten Reverse Stock Split

- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on September 6, 2017 -

Merrimack Appoints Thomas Needham As Chief Business Officer

Merrimack Appoints Thomas Needham As Chief Business Officer

Industry veteran to help shape and execute value creation strategy across Merrimack's broad development pipeline

Merrimack Announces Expansion Of Senior Management Team With Appointment Of Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources

Key Appointments to Help Drive Merrimack's Refocused Research and Clinical Development Strategy

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Merrimack Announces Management Change

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Merrimack To Present At The 2017 American Association For Cancer Research Annual Meeting

Presentations to include data on MM-310, a novel antibody-directed nanotherapeutic targeting EphA2, and istiratumab (MM-141), a monoclonal bispecific antibody that acts as a tetravalent inhibitor of IGF1-R and HER3

First Week Of MACK May 19th Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the May 19th expiration.

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

First Week of MACK April 21st Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.

TheStreet Quant Rating: E+ (Sell)